Assessment of anthracycline-induced cardiotoxicity with electrocardiography
Aim: Monitoring of anthracycline-induced cardiotoxicity with electrocardiography (ECG) and comparing ECG changes with findings on echocardiography (ECHO). Methods: A total of 26 adult acute leukemia patients (mean age 46.2 ± 12.4 years, 15 males) treated with 2–6 cycles of anthracycline-based chem...
Gespeichert in:
| Veröffentlicht in: | Experimental Oncology |
|---|---|
| Datum: | 2009 |
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | Englisch |
| Veröffentlicht: |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
2009
|
| Schlagworte: | |
| Online Zugang: | https://nasplib.isofts.kiev.ua/handle/123456789/136213 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Назва журналу: | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| Zitieren: | Assessment of anthracycline-induced cardiotoxicity with electrocardiography / J.M. Horacek, M. Jakl, J. Horackova, R. Pudil, L. Jebavy, J. Maly // Experimental Oncology. — 2009. — Т. 31, № 2. — С. 115–117. — Бібліогр.: 15 назв. — англ. |
Institution
Digital Library of Periodicals of National Academy of Sciences of Ukraine| _version_ | 1859692218426589184 |
|---|---|
| author | Horacek, J.M. Jakl, M. Horackova, J. Pudil, R. Jebavy, L. Maly, J. |
| author_facet | Horacek, J.M. Jakl, M. Horackova, J. Pudil, R. Jebavy, L. Maly, J. |
| citation_txt | Assessment of anthracycline-induced cardiotoxicity with electrocardiography / J.M. Horacek, M. Jakl, J. Horackova, R. Pudil, L. Jebavy, J. Maly // Experimental Oncology. — 2009. — Т. 31, № 2. — С. 115–117. — Бібліогр.: 15 назв. — англ. |
| collection | DSpace DC |
| container_title | Experimental Oncology |
| description | Aim: Monitoring of anthracycline-induced cardiotoxicity with electrocardiography (ECG) and comparing ECG changes with findings
on echocardiography (ECHO). Methods: A total of 26 adult acute leukemia patients (mean age 46.2 ± 12.4 years, 15 males)
treated with 2–6 cycles of anthracycline-based chemotherapy (CT) were studied. Cardiac evaluation was performed at the baseline
(before CT), after first CT, after last CT (cumulative anthracycline dose 464.3 ± 117.5 mg/m2
) and circa 6 months after CT.
Time ECG parameters, QRS voltage, presence of repolarization changes, arrhythmias and other abnormalities were evaluated.
Results: During treatment and follow-up, we found a statistical significant QTc interval prolongation — 414.7 ± 16.0 ms (before
CT), 419.6 ± 21.6 ms(after first CT), 428.0 ± 16.2 ms(after last CT) and 430.1 ± 18.4 ms(6 months after CT). Significant QTc
interval prolongation (> 450 ms) occurred in 3 patients after first CT, in 4 patients after last CT and in 5 patients within 6 months
after CT. Significant total QRS voltage lowering in the limb leads (> 1.0 mV versus before CT) occurred in 3 patients after first
CT, in 5 patients after last CT and in 6 patients within 6 months after CT. We found a statistically significant correlation between
decreased QRS voltage, QTc interval prolongation and left ventricular (LV) dysfunction on ECHO. Repolarization changes associated
with oncology treatment were present in 9 patients within 6 months after CT. Conclusion: Anthracycline treatment is associated
with changes in electrical activity of the myocardium. Prolonged QTc interval represents a risk for development of malignant
ventricular arrhythmias. Decreased QRS voltage and prolonged QTc interval after anthracycline treatment could correlate with
LV dysfunction on ECHO. Further studies will be needed to prove whether these ECG changes could serve as an accessible and
non-invasive screening method indicating LV dysfunction after anthracycline treatment.
|
| first_indexed | 2025-11-30T23:50:47Z |
| format | Article |
| fulltext | |
| id | nasplib_isofts_kiev_ua-123456789-136213 |
| institution | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| issn | 1812-9269 |
| language | English |
| last_indexed | 2025-11-30T23:50:47Z |
| publishDate | 2009 |
| publisher | Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |
| record_format | dspace |
| spelling | Horacek, J.M. Jakl, M. Horackova, J. Pudil, R. Jebavy, L. Maly, J. 2018-06-16T07:26:34Z 2018-06-16T07:26:34Z 2009 Assessment of anthracycline-induced cardiotoxicity with electrocardiography / J.M. Horacek, M. Jakl, J. Horackova, R. Pudil, L. Jebavy, J. Maly // Experimental Oncology. — 2009. — Т. 31, № 2. — С. 115–117. — Бібліогр.: 15 назв. — англ. 1812-9269 https://nasplib.isofts.kiev.ua/handle/123456789/136213 Aim: Monitoring of anthracycline-induced cardiotoxicity with electrocardiography (ECG) and comparing ECG changes with findings on echocardiography (ECHO). Methods: A total of 26 adult acute leukemia patients (mean age 46.2 ± 12.4 years, 15 males) treated with 2–6 cycles of anthracycline-based chemotherapy (CT) were studied. Cardiac evaluation was performed at the baseline (before CT), after first CT, after last CT (cumulative anthracycline dose 464.3 ± 117.5 mg/m2 ) and circa 6 months after CT. Time ECG parameters, QRS voltage, presence of repolarization changes, arrhythmias and other abnormalities were evaluated. Results: During treatment and follow-up, we found a statistical significant QTc interval prolongation — 414.7 ± 16.0 ms (before CT), 419.6 ± 21.6 ms(after first CT), 428.0 ± 16.2 ms(after last CT) and 430.1 ± 18.4 ms(6 months after CT). Significant QTc interval prolongation (> 450 ms) occurred in 3 patients after first CT, in 4 patients after last CT and in 5 patients within 6 months after CT. Significant total QRS voltage lowering in the limb leads (> 1.0 mV versus before CT) occurred in 3 patients after first CT, in 5 patients after last CT and in 6 patients within 6 months after CT. We found a statistically significant correlation between decreased QRS voltage, QTc interval prolongation and left ventricular (LV) dysfunction on ECHO. Repolarization changes associated with oncology treatment were present in 9 patients within 6 months after CT. Conclusion: Anthracycline treatment is associated with changes in electrical activity of the myocardium. Prolonged QTc interval represents a risk for development of malignant ventricular arrhythmias. Decreased QRS voltage and prolonged QTc interval after anthracycline treatment could correlate with LV dysfunction on ECHO. Further studies will be needed to prove whether these ECG changes could serve as an accessible and non-invasive screening method indicating LV dysfunction after anthracycline treatment. The work was supported by research projects MO 0FVZ 0000503 (Czech Ministry of Defence) and MZO 00179906 (Czech Ministry of Health). en Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України Experimental Oncology Short communications Assessment of anthracycline-induced cardiotoxicity with electrocardiography Article published earlier |
| spellingShingle | Assessment of anthracycline-induced cardiotoxicity with electrocardiography Horacek, J.M. Jakl, M. Horackova, J. Pudil, R. Jebavy, L. Maly, J. Short communications |
| title | Assessment of anthracycline-induced cardiotoxicity with electrocardiography |
| title_full | Assessment of anthracycline-induced cardiotoxicity with electrocardiography |
| title_fullStr | Assessment of anthracycline-induced cardiotoxicity with electrocardiography |
| title_full_unstemmed | Assessment of anthracycline-induced cardiotoxicity with electrocardiography |
| title_short | Assessment of anthracycline-induced cardiotoxicity with electrocardiography |
| title_sort | assessment of anthracycline-induced cardiotoxicity with electrocardiography |
| topic | Short communications |
| topic_facet | Short communications |
| url | https://nasplib.isofts.kiev.ua/handle/123456789/136213 |
| work_keys_str_mv | AT horacekjm assessmentofanthracyclineinducedcardiotoxicitywithelectrocardiography AT jaklm assessmentofanthracyclineinducedcardiotoxicitywithelectrocardiography AT horackovaj assessmentofanthracyclineinducedcardiotoxicitywithelectrocardiography AT pudilr assessmentofanthracyclineinducedcardiotoxicitywithelectrocardiography AT jebavyl assessmentofanthracyclineinducedcardiotoxicitywithelectrocardiography AT malyj assessmentofanthracyclineinducedcardiotoxicitywithelectrocardiography |